Sector News

Takeover-hungry J&J hikes its Actelion bid past $26B

November 30, 2016
Life sciences

Actelion’s reportedly not interested in a straight-up takeover by suitor Johnson & Johnson. But the New Jersey drugmaker is, and it’s loading the pressure on.

The pharma giant has raised its offer for the Swiss biotech, Bloomberg’s sources say. The new proposed price isn’t known, but it’s a significant increase on the CHF 246 ($242) per share–or $26 billion–that Actelion previously rejected. That offer wasn’t public, though both companies disclosed late last week that they were engaged in deal talks. Actelion has also given J&J a peek at some of its financial information as part of the process, the news service says.

According to Reuters, that process has been going on informally for nearly two months, but the parties haven’t been able to move forward. The hang-up? Actelion would rather form a new entity with a piece of J&J, with the behemoth becoming a major shareholder of that new entity. J&J, on the other hand, wants to swallow Actelion whole.

It wasn’t always that way, Reuters says. The companies initially talked over a transaction without a big premium–such as a share deal or an asset swap. And Bloomberg says J&J is still open to talking through other deal structures in order to win over Actelion CEO Jean-Paul Clozel. Ultimately, though, J&J–which is looking for new revenue streams as biosimilar competition creeps up on blockbuster Remicade–wants control of Actelion, according to Bloomberg’s sources.

Actelion, a frequent subject of takeover buzz, hasn’t exactly been shy about the fact that it wants to keep flying solo. Clozel, who founded the company with his wife Martine–Actelion’s chief scientific officer–after leaving an exec post at Roche, told Bloomberg in April that “if we want to continue to create shareholder value, the best for us is to remain independent.”

Bankers, though, are working to get other Big Pharma players to make their own Actelion approaches, the Financial Times reported this week. Roche, Novartis and Sanofi have all popped up previously in chatter concerning potential suitors.

But Actelion has plenty of experience fending off unwanted suitors. Last year, the company reportedly dodged an $18.9 billion bid from fellow rare-disease drugmaker Shire, and in 2011 it resisted activist hedge fund Elliott Advisors.

By Carly Helfand

Source: Fierce Pharma

comments closed

Related News

January 22, 2023

Sun Pharma to buy Concert Pharmaceuticals for $576m

Life sciences

Sun Pharmaceutical Industries has signed a definitive agreement to buy all outstanding shares of Concert Pharmaceuticals in a deal valued at $576m. Under the deal, the company will buy all shares of Concert common stock through a tender offer for $8.00 per share in cash upfront payment.

January 22, 2023

Novo Nordisk diabetes pill wins FDA approval for first-line use

Life sciences

The Food and Drug Administration on Thursday approved Novo Nordisk’s diabetes pill Rybelsus as an initial treatment to lower blood sugar levels, a label expansion that will allow it to compete more directly with other oral drugs from Merck & Co. and Eli Lilly.

January 22, 2023

Bayer feeling more heat from activist investors, this time from Bluebell

Life sciences

Since making an ill-advised $63 billion buy of Monsanto in 2018, Bayer has faced heaps of pressure from investors that have called for the company to oust its leadership and to restructure. Now comes new pressure from a familiar source. Bluebell Capital Partners has bought an undisclosed stake in the company and is agitating for a breakup, sources told Reuters.

How can we help you?

We're easy to reach